NASDAQ:YTEN Yield10 Bioscience (YTEN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About Yield10 Bioscience Stock (NASDAQ:YTEN) Get Yield10 Bioscience alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume78,164 shsMarket Capitalization$257 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Yield10 Bioscience, Inc. is an agricultural bioscience company headquartered in Woburn, Massachusetts, that focuses on improving crop yield and performance through cutting-edge trait discovery and development. The company employs a proprietary platform to identify genes and pathways that control seed yield, oil content and abiotic stress tolerance. By leveraging tools such as gene editing, genomics and metabolic engineering, Yield10 aims to deliver step-change improvements in major row crops including canola, soybean, rice, wheat and corn. A core element of Yield10’s research strategy is the use of Camelina sativa, a fast-growing oilseed crop, as a model system for trait evaluation. Camelina serves as a rapid testbed for candidate yield genes, allowing the company to advance promising traits more quickly than in larger grain crops. Once traits are validated in Camelina, Yield10 works to translate those improvements into high-value commercial crops through greenhouse and field trials under a range of environmental conditions. The company’s pipeline includes multiple trait development programs aimed at boosting pod number, seed size and seed oil content. Yield10 supports its discovery and development efforts through collaborations and licensing agreements with leading agribusiness partners. These partnerships provide access to large-scale field trial capabilities and commercial germplasm, accelerating the path to market. Led by a management team of experienced professionals in agricultural biotechnology and crop science, Yield10 conducts research primarily in North America while pursuing global deployment of its technologies through strategic alliances with seed companies and other industry stakeholders.AI Generated. May Contain Errors. Read More Receive YTEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Yield10 Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. YTEN Stock News HeadlinesYield10 Bioscience (NASDAQ:YTEN) Stock Price Passes Above Two Hundred Day Moving Average - Here's WhyAugust 15, 2026 | americanbankingnews.comYield10 Bioscience Files for Chapter 11 BankruptcyDecember 6, 2024 | tipranks.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.August 20 at 1:00 AM | Awesomely (Ad)Yield10 Bioscience (OTC:YTEN) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comYield10 Bioscience (OTC:YTEN) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comYield10 Bioscience, Inc.: Yield10 Bioscience Announces Second Quarter 2024 Financial ResultsAugust 15, 2024 | finanznachrichten.deYield10 Bioscience Announces Second Quarter 2024 Financial ResultsAugust 14, 2024 | globenewswire.comYield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of AssetsJuly 17, 2024 | globenewswire.comSee More Headlines YTEN Stock Analysis - Frequently Asked Questions How were Yield10 Bioscience's earnings last quarter? Yield10 Bioscience, Inc. (NASDAQ:YTEN) issued its earnings results on Tuesday, November, 9th. The specialty chemicals company reported ($11.76) earnings per share for the quarter, topping the consensus estimate of ($15.60) by $3.84. The specialty chemicals company earned $0.09 million during the quarter, compared to the consensus estimate of $0.22 million. When did Yield10 Bioscience's stock split? Yield10 Bioscience's stock reverse split before market open on Friday, May 3rd 2024.The 1-24 reverse split was announced on Friday, May 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Yield10 Bioscience? Shares of YTEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Yield10 Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Yield10 Bioscience investors own include Canopy Growth (CGC), Kushco (KSHB), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE) and FuelCell Energy (FCEL). Company Calendar Last Earnings11/09/2021Today8/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Staples Industry Food Products Sub-IndustryAgricultural Products & Services Current SymbolNASDAQ:YTEN CIK1121702 Webwww.yield10bio.com Phone(617) 583-1700Fax617-583-1768Employees30Year Founded1992Profitability EPS (Trailing Twelve Months)($26.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.45 million Net MarginsN/A Pretax Margin-1,693.60% Return on EquityN/A Return on Assets-296.08% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.16 Sales & Book Value Annual Sales$60 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($4.97) per share Price / BookN/AMiscellaneous Outstanding Shares734,000Free Float689,000Market Cap$257 thousand OptionableNot Optionable Beta1.48 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:YTEN) was last updated on 8/20/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredLook at this $5 stock’s addressA small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...Freedom Financial | SponsoredOne Ticker Tied to a Major White House Move You Should KnowLarry Benedict made 274 million dollars for his clients by spotting major market moves before they happened. ...Brownstone Research | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Yield10 Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Yield10 Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.